Journal of diabetes and metabolic disorders

Heart and blood vessel outcomes with tirzepatide compared to semaglutide in type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with Type 2 diabetes.

  • Tirzepatide demonstrates improved blood sugar management in patients with Type 2 diabetes.
  • Weight loss is significantly greater with tirzepatide than with semaglutide in this population.
  • Tirzepatide shows non-inferiority to dulaglutide regarding cardiovascular risk reduction in patients with Type 2 diabetes.
  • The comparative effectiveness of tirzepatide and semaglutide for heart protection remains unclear.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jul '26
Heart health and biomarker changes over 2 years with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes
top 10% journal
journal article
Mar '26
Tirzepatide Compared to Dulaglutide or Semaglutide for Major Heart Problems in Type 2 Diabetes with Heart Disease
top 1% journal
cited by 1 paper
journal article
Sep '24
New cases of type 2 diabetes in adults with obesity treated with tirzepatide or semaglutide: real-world data from an international study
top 2% journal
cited by 30 papers
journal article
Jun '26
Real-world weight and blood sugar outcomes of tirzepatide versus semaglutide in people with obesity and type 2 diabetes
observational study
Mar '26
Heart and blood vessel outcomes after obesity treatment with Tirzepatide versus Semaglutide in adults without diabetes
cited by 1 paper
journal article
Sep '26
Risk of Asthma Attacks with Tirzepatide Compared to Semaglutide in People with Asthma and Type 2 Diabetes
top 20% journal
journal article
Nov '25
Heart-related results of semaglutide and tirzepatide in people with type 2 diabetes
🏆 top 0.1% journal
cited by 39 papers
journal article
Oct '25
Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes
top 20% journal
cited by 9 papers
journal article
Sep '25
Better Brain Blood Vessel Outcomes with Tirzepatide Compared to Semaglutide in Diabetic Patients After Heart Bypass Surgery
top 20% journal
cited by 5 papers
journal article
Sep '26
Treatment patterns and costs for US type 2 diabetes patients starting tirzepatide or semaglutide who reach treatment goals
top 20% journal
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief